The estimated Net Worth of David F Burgstahler is at least $298 Milion dollars as of 13 January 2020. Mr. Burgstahler owns over 1,250,000 units of Osmotica Pharmaceuticals Plc stock worth over $17,461,259 and over the last 12 years he sold OSMT stock worth over $280,700,154. In addition, he makes $68,750 as Director at Osmotica Pharmaceuticals Plc.
Sign up
Mr. Burgstahler OSMT stock SEC Form 4 insiders trading
David has made over 15 trades of the Osmotica Pharmaceuticals Plc stock since 2016, according to the Form 4 filled with the SEC. Most recently he bought 1,250,000 units of OSMT stock worth $6,250,000 on 13 January 2020.
The largest trade he's ever made was selling 3,000,000 units of Osmotica Pharmaceuticals Plc stock on 20 June 2017 worth over $44,610,000. On average, David trades about 806,671 units every 45 days since 2012. As of 13 January 2020 he still owns at least 15,730,864 units of Osmotica Pharmaceuticals Plc stock.
You can see the complete history of Mr. Burgstahler stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
David Burgstahler biography
David F. Burgstahler serves as Director of the Company. Mr. Burgstahler was a founding partner of Avista Capital Partners in 2005, and since 2009 has been President of Avista Capital Partners. Prior to forming Avista Capital Partners, Mr. Burgstahler was a partner of DLJ Merchant Banking Partners. Mr. Burgstahler was at DLJ Investment Banking from 1995 to 1997 and at DLJ Merchant Banking Partners from 1997 to 2005. Prior to that, Mr. Burgstahler worked at Andersen Consulting (now known as Accenture plc) and McDonnell Douglas (now known as The Boeing Company). Mr. Burgstahler currently serves as a director of Arcadia Consumer Healthcare, Inc., Cosette Pharmaceuticals, Inc., Inform Diagnostics, Inc., United BioSource Corporation and XIFIN, Inc. Mr. Burgstahler also previously served on the board of directors of AngioDynamics, Inc., Armored AutoGroup, Avista Healthcare Public Acquisition Corp., BioReliance Corp., ConvaTec Healthcare B S.a.r.l., Focus Diagnostics, Inc., INC Research Holdings, Inc., Lantheus Holdings, Inc., MPI Research, Inc., Strategic Partners, LLC, Visant Corp., Warner Chilcott PLC and WideOpenWest, Inc. Mr. Burgstahler is also a Trustee of the Trinity School in New York City. Mr. Burgstahler holds a B.S. in Aerospace Engineering from the University of Kansas and an M.B.A. from Harvard Business School. Mr. Burgstahler is being nominated to serve on our board of directors because of his extensive finance and management background, including over 20 years in banking and private equity finance, and his experience serving as a director for a diverse group of private and public companies.
What is the salary of David Burgstahler?
As the Director of Osmotica Pharmaceuticals Plc, the total compensation of David Burgstahler at Osmotica Pharmaceuticals Plc is $68,750. There are 11 executives at Osmotica Pharmaceuticals Plc getting paid more, with Brian Markison having the highest compensation of $4,338,620.
How old is David Burgstahler?
David Burgstahler is 51, he's been the Director of Osmotica Pharmaceuticals Plc since 2016. There are 11 older and 5 younger executives at Osmotica Pharmaceuticals Plc. The oldest executive at Osmotica Pharmaceuticals Plc is Fred Weiss, 78, who is the Independent Director.
What's David Burgstahler's mailing address?
David's mailing address filed with the SEC is 65 E 55th St #18, New York, NY 10022, USA.
Insiders trading at Osmotica Pharmaceuticals Plc
Over the last 6 years, insiders at Osmotica Pharmaceuticals Plc have traded over $0 worth of Osmotica Pharmaceuticals Plc stock and bought 6,343,800 units worth $31,350,366 . The most active insiders traders include David F Burgstahler, Sriram Venkataraman a Ltd Orbit Co Invest A 1 Llc.... On average, Osmotica Pharmaceuticals Plc executives and independent directors trade stock every 117 days with the average trade being worth of $1,173,603. The most recent stock trade was executed by James Schaub on 16 December 2021, trading 93,800 units of OSMT stock currently worth $100,366.
What does Osmotica Pharmaceuticals Plc do?
Osmotica Pharmaceuticals plc is a fully integrated biopharmaceutical company focused on the development and commercialization of specialty products that target markets with underserved patient populations. The company has a diverse portfolio consisting of promoted and non-promoted products, several of which incorporate Osmotica’s proprietary Osmodex® drug delivery system. RVL Pharmaceuticals, Inc. is the Company’s ophthalmic subsidiary supporting Upneeq®. Vertical Pharmaceuticals, LLC represents the Company’s diversified branded portfolio and Trigen Laboratories, LLC represents the Company’s non-promoted products, including complex generic formulations. Osmotica has operations in the United States, Argentina, and Hungary.
What does Osmotica Pharmaceuticals Plc's logo look like?
Complete history of Mr. Burgstahler stock trades at Angiodynamic Inc, Lantheus Inc, WideOpenWest Inc a Osmotica Pharmaceuticals Plc
Osmotica Pharmaceuticals Plc executives and stock owners
Osmotica Pharmaceuticals Plc executives and other stock owners filed with the SEC include:
-
Brian Markison,
Chairman of the Board, Chief Executive Officer -
Christopher Klein,
General Counsel, Secretary -
Tina deVries,
Executive Vice President - Research & Development -
James Schaub,
Chief Operating Officer, Executive Vice President -
Brian A. Markison,
Chairman, Pres & CEO -
Christopher A. Klein,
Gen. Counsel & Sec. -
James D. Schaub,
Exec. VP & COO -
Dr. Tina Marie deVries,
Exec. VP of R&D -
Andrew Einhorn,
Chief Financial Officer -
Fred Weiss,
Independent Director -
Gregory Cowan,
Independent Director -
David Burgstahler,
Director -
Sriram Venkataraman,
Director -
Juan Vergez,
Director -
Michael DeBiasi,
Independent Director -
Lisa Wilson,
IR Contact Officer -
Joachim Benes,
Director -
Andrew J. Einhorn CPA,
Chief Financial Officer -
Jarret Miller,
Exec. VP of HR -
Sergio Alegre,
VP of Global Compliance -
Capital Partners Iii Gp, L....,
-
Ltd Orbit Co Invest A 1 Llc...,
-
Foundation Harsaul,
10% owner -
Capital Partners Iii Gp, L....,